[Featured Stock] LabGenomics Rises on Spotlight of Liquid Biopsy Gene Editing Technology Adoption

The stock price of LabGenomics is showing a rise of over 20% during trading on the 1st. The news that the cancer early diagnosis company they collaborated with has increased diagnostic accuracy by introducing gene-editing technology into liquid biopsy for the first time in the world seems to have reflected expectations that it will benefit LabGenomics' diagnostic kit business.

As of 10:09 a.m. on the day, LabGenomics' stock price recorded 2,540 won, up 19.5% compared to the previous day. Jinseeker, which signed a memorandum of understanding (MOU) with LabGenomics for joint development of infectious disease molecular diagnostic kits, introduced gene-editing technology into liquid biopsy for the first time in the world.

For ultra-early cancer patients with a tumor size of 1㎤, the proportion of circulating tumor DNA (ctDNA) is only 0.022%, but existing liquid biopsies could not screen if ctDNA was below 0.1%. By using Jinseeker's gene-editing technology, the detection limit has been increased more than tenfold to 0.01%, enabling the detection of early-stage cancer. It is also reported that the diagnostic cost can be reduced to one-tenth compared to general liquid biopsy.

Meanwhile, LabGenomics is jointly developing molecular diagnostic kits with Jinseeker. By applying Jinseeker's ultra-precise CRISPR gene-editing technology, accurate genetic diagnosis is possible, achieving accuracy close to that of real-time polymerase chain reaction (RT-PCR) tests.

This content was produced with the assistance of AI translation services.